We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Exelixis, Inc. (NASDAQ:EXEL) stands against other best ...

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 5.6% in the ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell ...

RBC Capital raised the firm’s price target on Exelixis (EXEL) to $40 from $38 and keeps an Outperform rating on the shares. The firm notes ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

The trial evaluated the effect of triplet therapy with Exelixis’s Cabometyx and Bristol Myers Squibb’s Opdivo and Yervoy versus standard-of-care Opdivo and Yervoy combination as a front-line therapy ...

on Facebook and follow Exelixis on LinkedIn. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks.

Some of its key products include CABOMETYX, a drug for advanced renal cell carcinoma (RCC); and COMETRIQ capsules to treat progressive and metastatic medullary thyroid cancer. The company recently ...

Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification. The phase 3 COSMIC-313 trial evaluated Cabometyx ...